News
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasia Designed to resist competition from endogenous ACTH by maximizing ...
We expect to release the H1 2025 interim results of NTG Nordic Transport Group on the evening of August 11, 2025. A webcast and conference call will be held in the morning of August 12, 2025, at 10:00 ...
PhenQ has positioned itself as a leading best OTC fat-burning solution for men who want safe, structured weight support ...
Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm ...
Menerals, a new men’s health supplement brand based in San Diego, has officially launched with a no-nonsense approach to restoring male vitality. Focused on foundational nutrition and fueled by trace ...
Aliso Viejo, CA, July 11, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., the developer of the Life Backup Plan app, is issuing a ...
Classic steroids such as Dianabol, Trenbolone, Testosterone, and Deca Durabolin became mainstays in strength sports and ...
Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogen’s previous ...
(MMI), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex ...
Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 ...
Annette Slyman, Chief Operating Officer, Life Backup Plan by Galacxia, Inc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results